2,434
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE: MEDICAL ONCOLOGY

Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study

, , ORCID Icon, , , & show all
Pages 110-118 | Received 27 Feb 2018, Accepted 20 Sep 2018, Published online: 30 Oct 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Andreas Josefsson, Åsa Jellvert, Erik Holmberg, Klaus Brasso, Peter Meidahl Petersen, Sirpa Aaltomaa, Marjaana Luukkaa, Paul Verhagen, Ronald de Wit, Göran Ahlgren, Ove Andrén, Enrique Castellanos, Mihalj Seke, Anders Widmark & Jan-Erik Damber. (2023) Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14). Acta Oncologica 62:4, pages 372-380.
Read now

Articles from other publishers (3)

Harrison J. Hansford, Aidan G. Cashin, Matthew D. Jones, Sonja A. Swanson, Nazrul Islam, Susan R. G. Douglas, Rodrigo R. N. Rizzo, Jack J. Devonshire, Sam A. Williams, Issa J. Dahabreh, Barbra A. Dickerman, Matthias Egger, Xabier Garcia-Albeniz, Robert M. Golub, Sara Lodi, Margarita Moreno-Betancur, Sallie-Anne Pearson, Sebastian Schneeweiss, Jonathan A. C. Sterne, Melissa K. Sharp, Elizabeth A. Stuart, Miguel A. Hernán, Hopin Lee & James H. McAuley. (2023) Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials. JAMA Network Open 6:9, pages e2336023.
Crossref
Yoko Franchetti. (2021) Use of Propensity Scoring and Its Application to Real‐World Data: Advantages, Disadvantages, and Methodological Objectives Explained to Researchers Without Using Mathematical Equations. The Journal of Clinical Pharmacology 62:3, pages 304-319.
Crossref
Kerri Beckmann, Hans Garmo, Jan Adolfsson, Cecilia Bosco, Eva Johansson, David Robinson, Lars Holmberg, Par Stattin & Mieke Van Hemelrijck. (2019) Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. European Urology 75:4, pages 676-683.
Crossref